Wednesday, January 9, 2013
The publishing committee of the prestigious journal ARTHROSCOPY has awarded to prize for the best scientific work of year to a multicentre clinical trial that evaluated the efficacy and safety of the infiltration of plasma rich in growth factors (PRGF – ENDORET®) for treating symptoms due to arthrosis of the knee, in comparison with the use of hyaluronic acid.
The publishing committee of the prestigious journal ARTHROSCOPY has awarded to prize for the best scientific work of year to a multicentre clinical trial that evaluated the efficacy and safety of the infiltration of plasma rich in growth factors (PRGF – ENDORET®) for treating symptoms due to arthrosis of the knee, in comparison with the use of hyaluronic acid.
The paper, by Dr. Mikel Sánchez, trauma specialist from the USP La Esperanza de Vitoria, Dr. Eduardo Anitua, Scientific Director of BTI Biotechnology Institute and founder of PRGF – ENDORET® technology, among other professionals, was published in the June issue of the journal, one of the most prestigious in its field at international level.
The trial included 176 patients divided into parallel, random groups. Once a week for three consecutive weeks, 89 of them were infiltrated with PRGF – ENDORET® and the remaining 87 were treated with hyaluronic acid with the same system of dosage.
After 24 weeks of treatment, the trial results showed that with the application of PRGF – ENDORET® the sensation of pain was reduced in all the patients. Around 40% of the patient treated with PRGF – ENDORET® found their sensation of pain was reduced by up to 50%, thus improving their quality of life significantly. On the other hand, this percentage was 24% in the case of patients treated with hyaluronic acid.
This study also concluded that PRGF – ENDORET® does improve the function of the joint and reduce rigidity, thus increasing the mobility of arthrous knees.
In addition none of those treated with PRGF – ENDORET® presented adverse effects to the treatment, thus proving infiltration with plasma rich in growth factors to be biosafe in these clinical cases.
Three Health Centres participated in the trial: the Arthroscopic Surgery Unit of the Clinic USP La Esperanza, the Hospital Donostia and the Policlínica Guipúzcoa.
